# Red Violet, Inc.: financial statements, quarterly

RDVT · Nasdaq · CIK 1720116 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rdvt.md) · [Financials](/companies/rdvt/financials.md) · [Filings](/companies/rdvt/filings.md) · [Insiders](/companies/rdvt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rdvt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [15.8](/filings/0000950170-24-122438.md) | [15.1 d](/filings/0000950170-25-029184.md) | [17.5](/filings/0000950170-25-065854.md) | [19.1](/filings/0000950170-25-104191.md) | [19.1](/filings/0001193125-25-267173.md) | [19.6 d](/filings/0001193125-26-091708.md) | [22.0](/filings/0001193125-26-209274.md) | [21.8](/filings/0001193125-26-342598.md) | [23.1](/filings/0001193125-25-267173.md) | [23.4 d](/filings/0001193125-26-091708.md) | [25.8](/filings/0001193125-26-209274.md) | [26.7](/filings/0001193125-26-342598.md) |
| Operating income | $m | [1.8](/filings/0000950170-24-122438.md) | [(0.9) d](/filings/0000950170-25-029184.md) | [2.0](/filings/0000950170-25-065854.md) | [3.1](/filings/0000950170-25-104191.md) | [2.5](/filings/0001193125-25-267173.md) | [0.4 d](/filings/0001193125-26-091708.md) | [4.2](/filings/0001193125-26-209274.md) | [2.8](/filings/0001193125-26-342598.md) | [4.6](/filings/0001193125-25-267173.md) | [1.6 d](/filings/0001193125-26-091708.md) | [5.4](/filings/0001193125-26-209274.md) | [6.1](/filings/0001193125-26-342598.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(10.4)](/filings/0000950170-24-122438.md) | [0.6 d](/filings/0000950170-25-029184.md) | [0.6](/filings/0000950170-25-065854.md) | [0.7](/filings/0000950170-25-104191.md) | [1.1](/filings/0001193125-25-267173.md) | [(0.1) d](/filings/0001193125-26-091708.md) | [1.1](/filings/0001193125-26-209274.md) | [0.4](/filings/0001193125-26-342598.md) | [0.7](/filings/0001193125-25-267173.md) | [(0.8) d](/filings/0001193125-26-091708.md) | [1.4](/filings/0001193125-26-209274.md) | [1.5](/filings/0001193125-26-342598.md) |
| Net income | $m | [12.5](/filings/0000950170-24-122438.md) | [(1.1) d](/filings/0000950170-25-029184.md) | [1.8](/filings/0000950170-25-065854.md) | [2.6](/filings/0000950170-25-104191.md) | [1.7](/filings/0001193125-25-267173.md) | [0.9 d](/filings/0001193125-26-091708.md) | [3.4](/filings/0001193125-26-209274.md) | [2.7](/filings/0001193125-26-342598.md) | [4.2](/filings/0001193125-25-267173.md) | [2.8 d](/filings/0001193125-26-091708.md) | [4.4](/filings/0001193125-26-209274.md) | [5.0](/filings/0001193125-26-342598.md) |
| Diluted EPS | $ per share | [0.87](/filings/0000950170-24-122438.md) | not reported | [0.13](/filings/0000950170-25-065854.md) | [0.19](/filings/0000950170-25-104191.md) | [0.12](/filings/0001193125-25-267173.md) | not reported | [0.24](/filings/0001193125-26-209274.md) | [0.18](/filings/0001193125-26-342598.md) | [0.29](/filings/0001193125-25-267173.md) | not reported | [0.30](/filings/0001193125-26-209274.md) | [0.34](/filings/0001193125-26-342598.md) |
| Basic EPS | $ per share | [0.90](/filings/0000950170-24-122438.md) | not reported | [0.13](/filings/0000950170-25-065854.md) | [0.19](/filings/0000950170-25-104191.md) | [0.12](/filings/0001193125-25-267173.md) | not reported | [0.25](/filings/0001193125-26-209274.md) | [0.19](/filings/0001193125-26-342598.md) | [0.30](/filings/0001193125-25-267173.md) | not reported | [0.31](/filings/0001193125-26-209274.md) | [0.35](/filings/0001193125-26-342598.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [34.2](/filings/0000950170-23-060373.md) | [32.0](/filings/0000950170-25-029184.md) | [32.1](/filings/0000950170-24-055855.md) | [30.9](/filings/0000950170-24-092941.md) | [35.7](/filings/0000950170-24-122438.md) | [36.5](/filings/0001193125-26-091708.md) | [34.6](/filings/0000950170-25-065854.md) | [38.8](/filings/0000950170-25-104191.md) | [45.4](/filings/0001193125-25-267173.md) | [43.6](/filings/0001193125-26-342598.md) | [43.5](/filings/0001193125-26-209274.md) | [50.0](/filings/0001193125-26-342598.md) |
| Current assets | $m | [42.2](/filings/0000950170-23-060373.md) | [40.3](/filings/0000950170-25-029184.md) | [41.5](/filings/0000950170-24-055855.md) | [40.4](/filings/0000950170-24-092941.md) | [45.9](/filings/0000950170-24-122438.md) | [46.2](/filings/0001193125-26-091708.md) | [45.9](/filings/0000950170-25-065854.md) | [50.8](/filings/0000950170-25-104191.md) | [58.0](/filings/0001193125-25-267173.md) | [56.5](/filings/0001193125-26-342598.md) | [57.3](/filings/0001193125-26-209274.md) | [65.2](/filings/0001193125-26-342598.md) |
| Total assets | $m | [95.3](/filings/0000950170-23-060373.md) | [93.0](/filings/0000950170-25-029184.md) | [94.0](/filings/0000950170-24-055855.md) | [93.5](/filings/0000950170-24-092941.md) | [98.0](/filings/0000950170-24-122438.md) | [98.5](/filings/0001193125-26-091708.md) | [99.1](/filings/0000950170-25-065854.md) | [105](/filings/0000950170-25-104191.md) | [112](/filings/0001193125-25-267173.md) | [112](/filings/0001193125-26-342598.md) | [113](/filings/0001193125-26-209274.md) | [120](/filings/0001193125-26-342598.md) |
| Current liabilities | $m | [3.4](/filings/0000950170-23-060373.md) | [4.9](/filings/0000950170-25-029184.md) | [8.3](/filings/0000950170-24-055855.md) | [3.7](/filings/0000950170-24-092941.md) | [4.6](/filings/0000950170-24-122438.md) | [10.3](/filings/0001193125-26-091708.md) | [5.1](/filings/0000950170-25-065854.md) | [5.6](/filings/0000950170-25-104191.md) | [6.9](/filings/0001193125-25-267173.md) | [7.9](/filings/0001193125-26-342598.md) | [5.1](/filings/0001193125-26-209274.md) | [6.0](/filings/0001193125-26-342598.md) |
| Total liabilities | $m | [5.6](/filings/0000950170-23-060373.md) | [6.9](/filings/0000950170-25-029184.md) | [10.2](/filings/0000950170-24-055855.md) | [5.5](/filings/0000950170-24-092941.md) | [6.3](/filings/0000950170-24-122438.md) | [11.9](/filings/0001193125-26-091708.md) | [7.2](/filings/0000950170-25-065854.md) | [8.6](/filings/0000950170-25-104191.md) | [10.3](/filings/0001193125-25-267173.md) | [11.1](/filings/0001193125-26-342598.md) | [8.1](/filings/0001193125-26-209274.md) | [8.7](/filings/0001193125-26-342598.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [89.7](/filings/0000950170-24-122438.md) | [86.1](/filings/0001193125-26-091708.md) | [83.8](/filings/0000950170-25-104191.md) | [88.0](/filings/0001193125-25-267173.md) | [91.7](/filings/0001193125-25-267173.md) | [86.6](/filings/0001193125-26-342598.md) | [91.8](/filings/0001193125-26-342598.md) | [96.2](/filings/0001193125-26-342598.md) | [102](/filings/0001193125-25-267173.md) | [101](/filings/0001193125-26-342598.md) | [105](/filings/0001193125-26-342598.md) | [112](/filings/0001193125-26-342598.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [5.8 d](/filings/0000950170-24-122438.md) | [4.2 d](/filings/0000950170-25-029184.md) | [4.3](/filings/0000950170-25-065854.md) | [5.7 d](/filings/0000950170-25-104191.md) | [7.2 d](/filings/0001193125-25-267173.md) | [6.7 d](/filings/0001193125-26-091708.md) | [5.0](/filings/0001193125-26-209274.md) | [7.5 d](/filings/0001193125-26-342598.md) | [10.2 d](/filings/0001193125-25-267173.md) | [6.7 d](/filings/0001193125-26-091708.md) | [6.6](/filings/0001193125-26-209274.md) | [10.6 d](/filings/0001193125-26-342598.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-122438.md) | [0.0 d](/filings/0000950170-25-029184.md) | [0.1](/filings/0000950170-25-065854.md) | [0.1 d](/filings/0000950170-25-104191.md) | [0.0 d](/filings/0001193125-25-267173.md) | [0.0 d](/filings/0001193125-26-091708.md) | [0.1](/filings/0001193125-26-209274.md) | [0.2 d](/filings/0001193125-26-342598.md) | [0.2 d](/filings/0001193125-25-267173.md) | [0.1 d](/filings/0001193125-26-091708.md) | [0.1](/filings/0001193125-26-209274.md) | [0.1 d](/filings/0001193125-26-342598.md) |
| Share repurchases | $m | [0.3 d](/filings/0000950170-24-122438.md) | [2.5 d](/filings/0000950170-25-029184.md) | [1.4](/filings/0000950170-25-065854.md) | [4.4 d](/filings/0000950170-25-104191.md) | [0.0 d](/filings/0001193125-25-267173.md) | [0.0 d](/filings/0001193125-26-091708.md) | [0.0](/filings/0001193125-26-209274.md) | [0.0 d](/filings/0001193125-26-342598.md) | [0.7 d](/filings/0001193125-25-267173.md) | [0.3 d](/filings/0001193125-26-091708.md) | [2.7](/filings/0001193125-26-209274.md) | [0.4 d](/filings/0001193125-26-342598.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.8](/filings/0000950170-23-060373.md) | [14.2](/filings/0000950170-24-055855.md) | [14.2](/filings/0000950170-24-092941.md) | [14.3](/filings/0000950170-24-122438.md) | [14.2](/filings/0000950170-25-065854.md) | [14.1](/filings/0000950170-25-104191.md) | [14.3](/filings/0001193125-25-267173.md) | [14.5](/filings/0001193125-26-209274.md) | [14.6](/filings/0001193125-26-342598.md) | [14.6](/filings/0001193125-25-267173.md) | [14.4](/filings/0001193125-26-209274.md) | [14.5](/filings/0001193125-26-342598.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,046,975 at 2026-08-07, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342598.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.